NASDAQ$FLNA
Filana Therapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported a net income and provided updates on Phase 3 trials of Simufilam.
Cassava Sciences reported a net income of $25.0 million for the first quarter of 2024, a significant improvement compared to the net loss of $24.3 million for the same period in 2023. Both Phase 3 studies are fully enrolled, with approximately 1,900 patients randomized. Top-line data readout for the 52-week study (RETHINK-ALZ) is anticipated approximately year-end 2024, and for the 76-week study (REFOCUS-ALZ) approximately mid-year 2025.
- Net income for Q1 2024 was $25.0 million, compared to a net loss of $24.3 million in Q1 2023.
- Net cash used in operations was $19.1 million during the first quarter of 2024.
- Approximately 1,900 patients are randomized in both Phase 3 studies.
- Over 735 patients have completed the Phase 3 studies.
Headline financials
Revenue & EPS history
Cassava Sciences · Revenue · Quarterly
$0
Forward guidance
Cassava Sciences expects cash use for operations for the first half of 2024 to be $35 to $45 million, driven primarily by expenses for the clinical program in Alzheimer’s disease. Top-line data readout for the 52-week study (RETHINK-ALZ) is anticipated approximately year-end 2024. Top-line data readout for the 76-week study (REFOCUS-ALZ) is anticipated approximately mid-year 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+0.3%
Avg return
Earnings day
+1.0%
Avg return
5 days after
-5.1%
Avg return
30 days after
40%
23 / 57 earnings
Positive
+16.1%
Q4 2013
Best reaction
-12.6%
Q3 2014
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -0.5% | -16.7% | -9.0% | |
| Q3 2025 | +5.2% | -10.6% | -5.8% | |
| Q2 2025 | +5.3% | -3.9% | -7.5% | |
| Q1 2025 | -1.0% | +1.4% | -1.9% | |
| Q4 2024 | +3.3% | +17.1% | -42.1% | |
| Q3 2024 | +1.3% | -0.7% | -87.9% | |
| Q1 2024 | -2.3% | +9.0% | -7.0% | |
| Q4 2023 | -0.3% | -2.1% | -11.8% | |
| Q3 2023 | +3.3% | -8.2% | -2.8% | |
| Q2 2023 | -4.0% | -10.5% | +0.3% | |
| Q1 2023 | -4.5% | -3.9% | -2.2% | |
| Q4 2022 | +0.8% | +6.9% | -3.1% | |
| Q3 2022 | -1.2% | +6.6% | +4.6% | |
| Q2 2022 | -11.6% | +0.2% | +27.3% | |
| Q1 2022 | -5.3% | -6.3% | +37.7% | |
| Q4 2021 | -5.4% | -12.2% | -9.3% | |
| Q3 2021 | -7.6% | -22.8% | -43.8% | |
| Q2 2021 | +10.3% | +20.5% | -32.0% | |
| Q1 2021 | +12.2% | +30.0% | +55.6% | |
| Q4 2020 | -12.5% | -16.6% | -35.4% | |
| Q3 2020 | -6.5% | -21.8% | -26.4% | |
| Q2 2020 | +9.9% | +20.9% | +13.7% | |
| Q1 2020 | +0.0% | +22.8% | -67.0% | |
| Q4 2019 | +2.6% | -1.0% | +71.6% | |
| Q3 2019 | +4.7% | +3.1% | +13.4% | |
| Q2 2019 | -7.5% | -6.8% | -4.5% | |
| Q1 2019 | -2.7% | -5.3% | +1.8% | |
| Q4 2018 | -4.1% | +6.6% | -6.6% | |
| Q3 2018 | -4.1% | +0.0% | -9.0% | |
| Q2 2018 | -0.4% | +1.4% | -56.6% | |
| Q1 2018 | +12.1% | +11.5% | +26.4% | |
| Q4 2017 | -5.6% | -1.9% | +11.4% | |
| Q3 2017 | -2.6% | +3.4% | +15.0% | |
| Q2 2017 | -4.7% | +0.3% | -4.4% | |
| Q1 2017 | +2.6% | +10.4% | -19.1% | |
| Q4 2016 | +0.0% | +0.0% | +18.6% | |
| Q3 2016 | +15.4% | -1.5% | -7.7% | |
| Q2 2016 | +5.8% | +17.9% | +12.9% | |
| Q1 2016 | +3.4% | — | — | |
| Q4 2015 | +9.2% | — | — | |
| Q3 2015 | +0.0% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q1 2015 | +0.0% | — | — | |
| Q4 2014 | -4.4% | — | — | |
| Q3 2014 | -12.6% | — | — | |
| Q2 2014 | -4.0% | — | — | |
| Q1 2014 | -3.7% | — | — | |
| Q4 2013 | +16.1% | — | — | |
| Q3 2013 | -4.4% | — | — | |
| Q2 2013 | -4.1% | — | — | |
| Q1 2013 | +3.8% | — | — | |
| Q4 2012 | +3.9% | — | — | |
| Q4 2011 | -1.9% | — | — | |
| Q1 2011 | +3.6% | — | — | |
| Q3 2010 | +5.4% | — | — | |
| Q2 2010 | +9.1% | — | — | |
| Q1 2010 | -1.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro